A Case of Type 2 Diabetes Mellitus with Lung Cancer Suffered from Euglycemic Diabetic Ketosis Accompanied by Adrenal Insufficiency after Immune Checkpoint Inhibitors
Open Access
- 20 February 2024
- journal article
- research article
- Published by Hindawi Limited in Case Reports in Endocrinology
- Vol. 2024, 1-5
Abstract
A 74-year-old patient with type 2 diabetes mellitus received basal-bolus insulin, insulin secretagogues, and sodium glucose transporter 2 (SGLT2) inhibitors. After immune checkpoint inhibitor treatment for lung cancer, he suffered from depressed consciousness with a urinary ketone body (3+). When all hypoglycemic treatments were discontinued, his serum blood glucose remained at 121mg/dL. He was diagnosed with euglycemic diabetic ketosis. Endocrine loading tests revealed isolated adrenocorticotropic hormone (ACTH) deficiency as an immune-related adverse event. It was suggested that euglycemic diabetic ketosis was induced by the self-suspension of insulin and insulin secretagogues, adrenal insufficiency, SGLT2 inhibitors, and carbohydrate intake shortage.Keywords
This publication has 16 references indexed in Scilit:
- Nonsevere Diabetic Ketoacidosis and Adrenal Insufficiency: Exploring the Impact of Glucocorticoid Replacement on Metabolic Outcomes and ICU Length of StayCritical Care Explorations, 2020
- Euglycemic diabetic ketoacidosisEuropean Journal of Internal Medicine, 2019
- Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2018
- Management of Hyperglycemic CrisesMedical Clinics of North America, 2017
- Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 CanagliflozinJournal of Investigative Medicine High Impact Case Reports, 2017
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factorsJournal of Diabetes Investigation, 2015
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretionNature Medicine, 2015
- Cortisol increases gluconeogenesis in humans: its role in the metabolic syndromeClinical Science, 2001
- Failure to develop diabetic ketoacidosis in a newly presenting type 1 diabetic patientPostgraduate Medical Journal, 2001
- Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDMAmerican Journal of Physiology-Endocrinology and Metabolism, 1995